874-37-3

Basic information

• Product Name: 2,1,3-BENZOTHIADIAZOL-5-AMINE
• Synonyms: 2,1,3-BENZOTHIADIAZOL-5-AMINE;BENZO[1,2,5]THIADIAZOL-5-YLAMINE;BUTTPARK 95\50-71;5-Amino-2,1,3-benzothiadiazole;2,1,3-Benzothiadiazol-5-amine ,97%;2,1,3-benzothiadiazol-5-amine(SALTDATA: FREE);benzo[c][1,2,5]thiadiazol-5-aMine;(2,1,3-Benzothiadiazol-5-yl)amine
• CAS NO: 874-37-3
• Molecular Formula: C₆H₅N₃S
• Molecular Weight: 151.19
• Mol File: 874-37-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 112-115
• Boiling Point: 303 °C at 760 mmHg
• Flash Point: 137.1 °C
• Appearance: /
• Density: 1.485g/cm³
• Vapor Pressure: 0.000955mmHg at 25°C
• Refractive Index: 1.785
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.75±0.47(Predicted)
• CAS DataBase Reference: 2,1,3-BENZOTHIADIAZOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,1,3-BENZOTHIADIAZOL-5-AMINE(874-37-3)
• EPA Substance Registry System: 2,1,3-BENZOTHIADIAZOL-5-AMINE(874-37-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 874-37-3(Hazardous Substances Data)

Usage

General Description

2,1,3-Benzothiadiazol-5-amine is a chemical compound known for its organic heterocyclic compound classification. It is composed of a benzothiadiazole ring system making it a polycyclic organic compound, which contains two nitrogen atoms, one sulfur atom, and an amine group. Benzothiadiazoles are used as building blocks in organic synthesis, and are found in a variety of functional materials and biological systems. They are known for their wide range of interesting thermal, photophysical and electrochemical properties. However, detailed information regarding its toxicity, hazards, or environmental effects are not readily available, implying the need for careful handling and further research.

InChI:InChI=1/C6H5N3S/c7-4-1-2-5-6(3-4)9-10-8-5/h1-3H,7H2

Upstream product

• 16252-88-3 5-nitro-2,1,3-benzothiadiazole 
• 273-13-2 benzo[1,2,5]thiadiazole 
• 768-10-5 benzo[1,2,5]thiadiazol-5-ol 
• 21110-91-8 5-acetamidobenzo-2,1,3-thiadiazole 
• 99-56-9 4-Nitrophenylene-1,2-diamine 

Downstream Products

• 21110-91-8 5-acetamidobenzo-2,1,3-thiadiazole 
• 182012-46-0 4-nitro-benzenesulfonic acid benzo[1,2,5]thiadiazol-5-ylamide 
• 100191-31-9 6-chloro-benzo[1,2,5]thiadiazol-5-ylamine 
• 182012-50-6 sulfanilic acid benzo[1,2,5]thiadiazol-5-ylamide 
• 6662-87-9 4,5-Dichlor-benz<2,1,3>thiadiazol 
• 2518-38-9 2-Methyl-thiazolo-<4.5-g>-benz-2.1.3-thiodiazol 
• 2564-38-7 6H-thiazolo[5',4':3,4]benzo[1,2-c][1,2,5]thiadiazole-7-thione 
• 211-33-6 Thiazolo<5,4-e>benz-2,1,3-thiadiazole 
• 918106-11-3 N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea 
• 944447-37-4 2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 944447-82-9 C₂₈H₂₆Cl₂N₆OSSi 
• 944447-41-0 2-(2,1,3-benzothiadiazol-5-ylamino)-8-cyclopentyl-6-(2,6-dichlorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 768-10-5 benzo[1,2,5]thiadiazol-5-ol 
• 30536-22-2 5-amino-4-nitrobenzo[1,2,5]thiadiazole 

Relevant articles and documents

-

-

A practical and chemoselective reduction of nitroarenes to anilines using activated iron

Reduction of nitroarenes to anilines using activated iron generated by Fe/HCl or Zn/FeSO4 is described. A variety of functional groups such as alkyne, ketone, enone, nitrile, lactone, and aromatic halide are well tolerated under these conditions.

N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.